Gene–environment interactions contribute to schizophrenia aetiology. Neuregulin 1 is a well-established genetic risk factor for schizophrenia, and elevated expression of type III neuregulin 1 mRNA in the dorsolateral prefrontal cortex is observed in patients with a core risk haplotype. A mouse model of type III Nrg1 overexpression (Nrg1 III tg) possesses face and construct validity for schizophrenia; however, the sensitivity of these transgenic mice to environmental risk factors relevant to schizophrenia is unknown.
Aims:
To determine sensitivity of Nrg1 III tg mice to the psychostimulant methamphetamine (METH) in schizophrenia and addiction-relevant behavioural tests.
Methods:
We examined behavioural responses of adult male and female Nrg1 III tg mice METH (1–3 mg/kg) in schizophrenia-relevant paradigms (drug-induced locomotion, sensorimotor gating) and drug reward (conditioned place preference).
Results:
Male Nrg1 III tg mice were less sensitive to METH-induced stereotypies, yet showed a greater negative impact of METH on prepulse inhibition compared with wild type-like males. In contrast, female Nrg1 III tg mice were less sensitive to METH-induced locomotion than wild type-like females, while sensorimotor gating was similarly impaired by METH between the genotypes. There were no genotype differences for METH reward, or anxiety-like and exploratory behaviours.
Conclusions:
These results indicate that overexpression of Nrg1 type III modulates schizophrenia-relevant behaviours, and may help to explain increased sensitivity to the psychoactive effects of METH in patients with schizophrenia.
AliSFKordsmeierKJGoughB (1995) Drug-induced circling preference in rats. Correlation with monoamine levels. Mol Neurobiol11: 145–154.
2.
BareDJBecker-CataniaSGDeVriesGH (2011) Differential localization of neuregulin-1 type III in the central and peripheral nervous system. Brain Res1369: 10–20.
3.
BiLLSunXDZhangJ, et al. (2015) Amygdala NRG1-ErbB4 is critical for the modulation of anxiety-like behaviors. Neuropsychopharmacology40: 974–986.
4.
BoucherAAArnoldJCDuffyL, et al. (2007) Heterozygous neuregulin 1 mice are more sensitive to the behavioural effects of Delta9-tetrahydrocannabinol. Psychopharmacology192: 325–336.
5.
BraffDLGeyerMASwerdlowNR (2001) Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology156: 234–258.
6.
BrownAS (2011) The environment and susceptibility to schizophrenia. Prog Neurobiol93: 23–58.
7.
CallaghanRCCunninghamJKAllebeckP, et al. (2012) Methamphetamine use and schizophrenia: A population-based cohort study in California. Am J Psychiatry169: 389–396.
8.
CaspiAMoffittTECannonM, et al. (2005) Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry57: 1117–1127.
9.
ChartoffEHMarckBTMatsumotoAM, et al. (2001) Induction of stereotypy in dopamine-deficient mice requires striatal D1 receptor activation. Proc Natl Acad Sci U S A98: 10451–10456.
10.
ChenCHsuFCLiCW, et al. (2019) Structural, functional, and neurochemical neuroimaging of methamphetamine-associated psychosis: A systematic review. Psychiatry Res Neuroimaging292: 23–31.
11.
ChenCKLinSKShamPC, et al. (2005) Morbid risk for psychiatric disorder among the relatives of methamphetamine users with and without psychosis. Am J Med Genet B Neuropsychiatr Genet136: 87–91.
12.
ChesworthRBrownRMKimJH, et al. (2013) The metabotropic glutamate 5 receptor modulates extinction and reinstatement of methamphetamine-seeking in mice. PLoS One8: e68371.
13.
ChesworthRBrownRMKimJH, et al. (2016) Adenosine 2A receptors modulate reward behaviours for methamphetamine. Addict Biol21: 407–421.
14.
ChesworthRDowneyLLoggeW, et al. (2012) Cognition in female transmembrane domain neuregulin 1 mutant mice. Behav Brain Res226: 218–223.
15.
ChiouLCLeeHJErnstM, et al. (2018) Cerebellar alpha6 -subunit-containing GABAA receptors: A novel therapeutic target for disrupted prepulse inhibition in neuropsychiatric disorders. Br J Pharmacol175: 2414–2427.
16.
CunninghamCLGremelCMGroblewskiPA (2006) Drug-induced conditioned place preference and aversion in mice. Nat Protoc1: 1662–1670.
17.
DaskalakisNPBinderEB (2015) Schizophrenia in the spectrum of gene-stress interactions: The FKBP5 example. Schizophr Bull41: 323–329.
18.
DavisJEyreHJackaFN, et al. (2016) A review of vulnerability and risks for schizophrenia: Beyond the two hit hypothesis. Neurosci Biobehav Rev65: 185–194.
19.
DluzenDELiuB (2008) Gender differences in methamphetamine use and responses: A review. Gend Med5: 24–35.
20.
DluzenDEMcDermottJL (2002) Estrogen, anti-estrogen, and gender: differences in methamphetamine neurotoxicity. Ann N Y Acad Sci965: 136–156.
21.
European Network of National Networks Studying Gene-Environment Interactions in Schizophrenia; van OsJRuttenBPMyin-GermeysI, et al. (2014) Identifying gene-environment interactions in schizophrenia: Contemporary challenges for integrated, large-scale investigations. Schizophr Bull40: 729–736.
22.
FeierGValvassoriSSLopes-BorgesJ, et al. (2012) Behavioral changes and brain energy metabolism dysfunction in rats treated with methamphetamine or dextroamphetamine. Neurosci Lett530: 75–79.
23.
GengFZhangJWuJL, et al. (2016) Neuregulin 1-ErbB4 signaling in the bed nucleus of the stria terminalis regulates anxiety-like behavior. Neuroscience329: 182–192.
24.
GouHWenDMaC, et al. (2015) Protective effects of cholecystokinin-8 on methamphetamine-induced behavioral changes and dopaminergic neurodegeneration in mice. Behav Brain Res283: 87–96.
25.
GrantKMLeVanTDWellsSM, et al. (2012) Methamphetamine-associated psychosis. J Neuroimmune Pharmacol7: 113–139.
26.
GuptaRQaiserBHeL, et al. (2017) Neuregulin signaling pathway in smoking behavior. Transl Psychiatry7: e1212.
27.
HanSYangBZKranzlerHR, et al. (2012) Linkage analysis followed by association show NRG1 associated with cannabis dependence in African Americans. Biol Psychiatry72: 637–644.
28.
HarrisonPJ (2015) Recent genetic findings in schizophrenia and their therapeutic relevance. J Psychopharmacol29: 85–96.
29.
HarrisonPJLawAJ (2006) Neuregulin 1 and schizophrenia: Genetics, gene expression, and neurobiology. Biol Psychiatry60: 132–140.
30.
IkedaMOkahisaYAleksicB, et al. (2013) Evidence for shared genetic risk between methamphetamine-induced psychosis and schizophrenia. Neuropsychopharmacology38: 1864–1870.
31.
JanoutovaJJanackovaPSeryO, et al. (2016) Epidemiology and risk factors of schizophrenia. Neuro Endocrinol Lett37: 1–8.
32.
KarlT (2013) Neuregulin 1: A prime candidate for research into gene-environment interactions in schizophrenia? Insights from genetic rodent models. Front Behav Neurosci7: 106.
33.
KarlTBurneTHJvan den BuuseM, et al. (2011) Do transmembrane domain neuregulin 1 mutant mice exhibit a reliable sensorimotor gating deficit?Behav Brain Res223: 336–341.
34.
KarlTDuffyLScimoneA, et al. (2007) Altered motor activity, exploration and anxiety in heterozygous neuregulin 1 mutant mice: implications for understanding schizophrenia. Genes Brain Behav6: 677–687.
35.
KatoTAbeYHirokawaS, et al. (2015) Neurobehavioral differences between mice receiving distinct neuregulin variants as neonates; impact on sensitivity to MK-801. Curr Mol Med15: 222–236.
36.
KatoTAbeYSotoyamaH, et al. (2011) Transient exposure of neonatal mice to neuregulin-1 results in hyperdopaminergic states in adulthood: implication in neurodevelopmental hypothesis for schizophrenia. Mol Psychiatry16: 307–320.
37.
KishiTFukuoYOkochiT, et al. (2011) Serotonin 6 receptor gene is associated with methamphetamine-induced psychosis in a Japanese population. Drug Alcohol Depend113: 1–7.
38.
KishiTTsunokaTIkedaM, et al. (2010) Serotonin 1A receptor gene is associated with Japanese methamphetamine-induced psychosis patients. Neuropharmacology58: 452–456.
39.
KuczenskiRSegalDS (1999) Sensitization of amphetamine-induced stereotyped behaviors during the acute response: Role of D1 and D2 dopamine receptors. Brain Res822: 164–174.
40.
LaiCCLeeLJYinHS (2014) Behavioral and neurochemical changes induced by repetitive combined treatments of ketamine and amphetamine in mice. Neurochem Res39: 2180–2188.
41.
LedonneANobiliALatagliataEC, et al. (2015) Neuregulin 1 signalling modulates mGluR1 function in mesencephalic dopaminergic neurons. Mol Psychiatry20: 959–973.
42.
LongLEAndersonPFrankE, et al. (2015) Neuregulin 1 expression and electrophysiological abnormalities in the Neuregulin 1 transmembrane domain heterozygous mutant mouse. PLoS One10: e0124114.
43.
LongLEChesworthRArnoldJC, et al. (2010) A follow-up study: Acute behavioural effects of Delta(9)-THC in female heterozygous neuregulin 1 transmembrane domain mutant mice. Psychopharmacology211: 277–289.
44.
McKetinRHickeyKDevlinK, et al. (2010) The risk of psychotic symptoms associated with recreational methamphetamine use. Drug Alcohol Rev29: 358–363.
45.
MahoneyJJ3rdHawkinsRYDe La GarzaR2nd, et al. (2010) Relationship between gender and psychotic symptoms in cocaine-dependent and methamphetamine-dependent participants. Gend Med7: 414–421.
46.
MeiLXiongWC (2008) Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev Neurosci9: 437–452.
47.
MendrekAMancini-MarieA (2015) Sex/gender differences in the brain and cognition in schizophrenia. Neurosci Biobehav Rev. Epub ahead of print 30 December 2015. DOI: 10.1016/j.neubiorev.2015.10.013.
48.
Milesi-HalleAMcMillanDELaurenzanaEM, et al. (2007) Sex differences in (+)-amphetamine- and (+)-methamphetamine-induced behavioral response in male and female Sprague-Dawley rats. Pharmacol Biochem Behav86: 140–149.
49.
MisiakBStrameckiFGawedaL, et al. (2018) Interactions between variation in candidate genes and environmental factors in the etiology of schizophrenia and bipolar disorder: A systematic review. Mol Neurobiol55: 5075–5100.
50.
MoriTShibasakiMOgawaY, et al. (2013) Comparison of the behavioral effects of bupropion and psychostimulants. Eur J Pharmacol718: 370–375.
51.
MostaidMSLloydDLibergB, et al. (2016) Neuregulin-1 and schizophrenia in the genome-wide association study era. Neurosci Biobehav Rev68: 387–409.
52.
MoySSPerezAKollerBH, et al. (2006) Amphetamine-induced disruption of prepulse inhibition in mice with reduced NMDA receptor function. Brain Res1089: 186–194.
53.
MyersREAndersonLIDluzenDE (2003) Estrogen, but not testosterone, attenuates methamphetamine-evoked dopamine output from superfused striatal tissue of female and male mice. Neuropharmacology44: 624–632.
54.
NambaHOkuboTNawaH (2016) Perinatal exposure to neuregulin-1 results in disinhibition of adult midbrain dopaminergic neurons: Implication in schizophrenia modeling. Sci Rep6: 22606.
55.
OkumuraTOkochiTKishiT, et al. (2011) Genetic association analysis of NOS1 and methamphetamine-induced psychosis among Japanese. Curr Neuropharmacol9: 155–159.
56.
OlayaJCHeusnerCLMatsumotoM, et al. (2018a) Schizophrenia-relevant behaviours of female mice overexpressing neuregulin 1 type III. Behav Brain Res353: 227–235.
57.
OlayaJCHeusnerCLMatsumotoM, et al. (2018b) Overexpression of neuregulin 1 type III confers hippocampal mRNA alterations and schizophrenia-like behaviors in mice. Schizophr Bull44: 865–875.
PiazzaPVDeroche-GamonentVRouge-PontF, et al. (2000) Vertical shifts in self-administration dose-response functions predict a drug-vulnerable phenotype predisposed to addiction. J Neurosci20: 4226–4232.
60.
RenQZhangJCFujitaY, et al. (2013) Effects of TrkB agonist 7,8-dihydroxyflavone on sensory gating deficits in mice after administration of methamphetamine. Pharmacol Biochem Behav106: 124–127.
61.
RipkeSO’DushlaineCChambertK, et al. (2013) Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat Genet45: 1150–1159.
62.
SbisaAvan den BuuseMGogosA (2018) The effect of estrogenic compounds on psychosis-like behaviour in female rats. PLoS One13: e0193853.
63.
SearlesRVYooMJHeJR, et al. (2000) Sex differences in GABA turnover and glutamic acid decarboxylase (GAD(65) and GAD(67)) mRNA in the rat hypothalamus. Brain Res878: 11–19.
64.
ShimosatoKSaitoT (1993) Suppressive effect of cycloheximide on behavioral sensitization to methamphetamine in mice. Eur J Pharmacol234: 67–75.
65.
SpencerJRDarbyshireKMBoucherAA, et al. (2012) Adolescent neuregulin 1 heterozygous mice display enhanced behavioural sensitivity to methamphetamine. Prog Neuropsychopharmacol Biol Psychiatry39: 376–381.
66.
StefanssonHSarginsonJKongA, et al. (2003) Association of neuregulin 1 with schizophrenia confirmed in a Scottish population. Am J Hum Genet72: 83–87.
67.
StefanssonHSigurdssonESteinthorsdottirV, et al. (2002) Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet71: 877–892.
68.
SuryavanshiPSUgaleRRYilmazer-HankeD, et al. (2014) GluN2C/GluN2D subunit-selective NMDA receptor potentiator CIQ reverses MK-801-induced impairment in prepulse inhibition and working memory in Y-maze test in mice. Br J Pharmacol171: 799–809.
69.
TomiyamaKKatoRHaraY, et al. (2013) Phenotypic characterization of orofacial movement topography in mutants with disruption of amino acid mechanisms: glutamate N2A/B/D [GluRepsilon1/2/4] subtypes and the GABA synthesizing enzyme GAD65. Neuroscience250: 743–754.
70.
TsunokaTKishiTIkedaM, et al. (2011) No association between GRM3 and Japanese methamphetamine-induced psychosis. Curr Neuropharmacol9: 160–162.
71.
TsunokaTKishiTKitajimaT, et al. (2010) Association analysis of GRM2 and HTR2A with methamphetamine-induced psychosis and schizophrenia in the Japanese population. Prog Neuropsychopharmacol Biol Psychiatry34: 639–644.
72.
VahtMLaasKKiiveE, et al. (2017) A functional neuregulin-1 gene variant and stressful life events: Effect on drug use in a longitudinal population-representative cohort study. J Psychopharmacol31: 54–61.
73.
WearneTACornishJL (2018) A comparison of methamphetamine-induced psychosis and schizophrenia: A review of positive, negative, and cognitive symptomatology. Front Psychiatry9: 491.
74.
WearneTACornishJL (2019) Inhibitory regulation of the prefrontal cortex following behavioral sensitization to amphetamine and/or methamphetamine psychostimulants: A review of GABAergic mechanisms. Prog Neuropsychopharmacol Biol Psychiatry95: 109681.
75.
WeickertCSTiwariYSchofieldPR, et al. (2012) Schizophrenia-associated HapICE haplotype is associated with increased NRG1 type III expression and high nucleotide diversity. Transl Psychiatry2: e104.
76.
WilliamsNMPreeceASpurlockG, et al. (2003) Support for genetic variation in neuregulin 1 and susceptibility to schizophrenia. Mol Psychiatry8: 485–487.
77.
ZhaoXShiYTangJ, et al. (2004) A case control and family based association study of the neuregulin1 gene and schizophrenia. J Med Genet41: 31–34.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
